OncoMatch/Clinical Trials/NCT06600321
A Study to Evaluate ALN-BCAT in Patients With Hepatocellular Carcinoma
Is NCT06600321 recruiting? Yes, currently enrolling (May 2026). This Phase 1 trial studies multiple treatments including ALN-BCAT and Pembrolizumab for advanced hepatocellular carcinoma.
Treatment: ALN-BCAT · Pembrolizumab — The purpose of the dose escalation part of the study is to characterize the safety and tolerability of ALN-BCAT as monotherapy and in combination with pembrolizumab; and to determine the recommended dose(s) for expansion (RDFE) of ALN-BCAT as monotherapy and in combination with pembrolizumab. The purpose of the dose expansion part of the of the study is to evaluate the antitumor activity of ALN-BCAT as monotherapy and in combination with pembrolizumab; to characterize the safety and tolerability of ALN-BCAT as monotherapy and in combination with pembrolizumab.
Check if I qualifyExtracted eligibility criteria
Cancer type
Hepatocellular Carcinoma
Prior therapy
Must have received: systemic therapy — unresectable advanced or metastatic disease
Has had at least one line of systemic therapy for unresectable advanced or metastatic disease
Cannot have received: anti-cancer therapy or investigational drugs
Has received anti-cancer therapy or investigational drugs ≤3 weeks prior to the first dose of study drug
Lab requirements
Liver function
child-pugh class a or b7
Structured fields extracted by AI. May contain errors — verify against the official protocol.
US trial sites
- Clinical Trial Site · Phoenix, Arizona
- Clinical Trial Site · La Jolla, California
- Clinical Trial Site · Los Angeles, California
- Clinical Trial Site · Jacksonville, Florida
- Clinical Trial Site · Atlanta, Georgia
Showing up to 5 US sites. See all sites on ClinicalTrials.gov →
Could you qualify for this trial?
Enter your biomarker results to see how this trial's eligibility criteria match your specific cancer profile.
Check if I qualify